|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15471548154915501551155215531554155515561557...15771578» |
- Farydak (panobinostat) / Secura Bio
Phase classification, Combination therapy, Metastases: Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers (clinicaltrials.gov) - Jun 13, 2014
P1, N=50, Recruiting, Sponsor: Medical University of South Carolina
Phase classification: P1/2 --> P1
- IO biomarker: Molecular-Guided Therapy for Childhood Cancer (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=56, Not yet recruiting, Sponsor: Giselle Sholler
- | temozolomide / Generic mfg.
New P2 trial: NRG-BN001: Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Jun 13, 2014
P2, N=576, Not yet recruiting, Sponsor: Radiation Therapy Oncology Group
- Trial primary completion date: MRI in Pre-operative Radiotherapy for Soft Tissue Sarcoma: MISTS Study (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=15, Recruiting, Sponsor: Christie Hospital NHS Foundation Trust
Phase classification: P1/2 --> P1 Trial primary completion date: Sep 2015 --> Feb 2016
- Trial initiation date: MRI in Pre-operative Radiotherapy for Soft Tissue Sarcoma: MISTS Study (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=15, Recruiting, Sponsor: Christie Hospital NHS Foundation Trust
Trial primary completion date: Sep 2015 --> Feb 2016 Initiation date: Sep 2013 --> Feb 2014
- Enrollment open: MRI in Pre-operative Radiotherapy for Soft Tissue Sarcoma: MISTS Study (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=15, Recruiting, Sponsor: Christie Hospital NHS Foundation Trust
Initiation date: Sep 2013 --> Feb 2014 Not yet recruiting --> Recruiting
- || Ibrance (palbociclib) / Pfizer
Trial primary completion date, Metastases: PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma (clinicaltrials.gov) - Jun 8, 2014
P2, N=86, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2014 --> Sep 2015
- ||| Ibrance (palbociclib) / Pfizer
Enrollment closed, Metastases: PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma (clinicaltrials.gov) - Jun 8, 2014
P2, N=86, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: Sep 2014 --> Sep 2015 Recruiting --> Active, not recruiting
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Enrollment change, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Jun 8, 2014
P2, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=92 --> 30
- RG4733 / Roche
Enrollment change, IO biomarker: Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma (clinicaltrials.gov) - Jun 8, 2014
P2, N=47, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=92 --> 30 N=60 --> 47
- ||| Enrollment change: Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection (clinicaltrials.gov) - Jun 5, 2014
P2, N=70, Completed, Sponsor: GE Healthcare
N=60 --> 47 N=45 --> 70
- humanised dinutuximab (Hu14.18K322A) / St. Jude Children's Research Hospital
Clinical: Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody (clinicaltrials.gov) - Jun 4, 2014
P=N/A, N=100, Not yet recruiting, Sponsor: St. Jude Children's Research Hospital
- Recentin (cediranib) / AstraZeneca
Trial primary completion date: Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Jun 4, 2014
P2, N=73, Recruiting, Sponsor: National Cancer Institute (NCI)
N=45 --> 70 Trial primary completion date: Jul 2014 --> Jul 2016
- Recentin (cediranib) / AstraZeneca
Trial primary completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Jun 4, 2014
P2, N=47, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2014 --> Jul 2016 Trial primary completion date: Jun 2014 --> Apr 2016
- imetelstat (GRN163L) / Geron
Trial initiation date: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Jun 2, 2014
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
Trial primary completion date: Jun 2014 --> Apr 2016 Initiation date: Jan 2014 --> Jun 2014
- Tasigna (nilotinib) / Novartis, Inhibikase
Trial primary completion date, Stroma, Metastases: Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib (clinicaltrials.gov) - Jun 1, 2014
P4, N=40, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Jan 2014 --> Jun 2014 Trial primary completion date: Dec 2013 --> Dec 2015
- Trial primary completion date: IMRT Lower Limb Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 1, 2014
P2, N=59, Completed, Sponsor: University Health Network, Toronto
Trial primary completion date: Dec 2013 --> Dec 2015 Trial primary completion date: May 2014 --> May 2013
- | Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment open, Stroma, Metastases: Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib (clinicaltrials.gov) - Jun 1, 2014
P4, N=40, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: May 2014 --> May 2013 Active, not recruiting --> Recruiting
- | Hiltonol (poly-ICLC) / Oncovir
Enrollment closed: Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) (clinicaltrials.gov) - Jun 1, 2014
P2, N=20, Active, not recruiting, Sponsor: Dr. Nina Bhardwaj
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion: IMRT Lower Limb Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 1, 2014
P2, N=59, Completed, Sponsor: University Health Network, Toronto
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- sorafenib / Generic mfg.
Enrollment change, Metastases: Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer (clinicaltrials.gov) - May 29, 2014
P2, N=56, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=74 --> 56
- sorafenib / Generic mfg.
Trial completion, Metastases: Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer (clinicaltrials.gov) - May 29, 2014
P2, N=56, Completed, Sponsor: National Cancer Institute (NCI)
N=74 --> 56 Active, not recruiting --> Completed
- irinotecan / Generic mfg.
Trial primary completion date, Combination therapy: Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas (clinicaltrials.gov) - May 29, 2014
P1, N=0, Withdrawn, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Trial primary completion date: Jun 2019 --> May 2014
- irinotecan / Generic mfg.
Trial withdrawal, Combination therapy: Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas (clinicaltrials.gov) - May 29, 2014
P1, N=0, Withdrawn, Sponsor: City of Hope Medical Center
Trial primary completion date: Jun 2019 --> May 2014 Not yet recruiting --> Withdrawn
- irinotecan / Generic mfg.
Enrollment change, Combination therapy: Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas (clinicaltrials.gov) - May 29, 2014
P1, N=0, Withdrawn, Sponsor: City of Hope Medical Center
Not yet recruiting --> Withdrawn N=40 --> 0
- | veliparib (ABT-888) / AbbVie
New P2/3 trial, Combination therapy, PARP Biomarker: A071102: Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - May 29, 2014
P2/3, N=400, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- RG4733 / Roche
Enrollment change, Combination therapy: RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - May 29, 2014
P1, N=24, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=40 --> 0 N=34 --> 24
- thalidomide / Generic mfg.
Trial primary completion date: Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall (clinicaltrials.gov) - May 28, 2014
P2, N=23, Terminated, Sponsor: National Cancer Institute (NCI)
N=34 --> 24 Trial primary completion date: Sep 2011 --> Mar 2009
- | gefitinib / Generic mfg.
Trial completion: Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas (clinicaltrials.gov) - May 27, 2014
P1/2, N=69, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2011 --> Mar 2009 Active, not recruiting --> Completed
- carboplatin / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed, Surgery: Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer (clinicaltrials.gov) - May 27, 2014
P1, N=20, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial primary completion date: Evaluation of a New EUS-guided Needle (ProCore) Comparing to EUS-TCB Needle (Quick-Core) (clinicaltrials.gov) - May 27, 2014
P=N/A, N=76, Recruiting, Sponsor: Indiana University
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2014 --> Jan 2015
- Trial completion date: Evaluation of a New EUS-guided Needle (ProCore) Comparing to EUS-TCB Needle (Quick-Core) (clinicaltrials.gov) - May 27, 2014
P=N/A, N=76, Recruiting, Sponsor: Indiana University
Trial primary completion date: Jan 2014 --> Jan 2015 Trial completion date: Jan 2014 --> Jan 2015
- ||||| selurampanel (BGG492) / Novartis
New P2 trial: Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 (clinicaltrials.gov) - May 27, 2014
P2, N=77, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- || Tasigna (nilotinib) / Novartis, Inhibikase
Trial primary completion date: Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study (clinicaltrials.gov) - May 26, 2014
P4, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jan 2014 --> Jan 2015 Trial primary completion date: Jul 2023 --> May 2024
- buparlisib (AN2025) / Novartis, Adlai Nortye
Trial primary completion date, Combination therapy, Stroma: A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients (clinicaltrials.gov) - May 26, 2014
P1, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2023 --> May 2024 Trial primary completion date: Sep 2014 --> Dec 2014
- bortezomib / Generic mfg., temozolomide / Generic mfg.
Trial primary completion date, Combination therapy: Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma (clinicaltrials.gov) - May 26, 2014
P2, N=70, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Trial primary completion date: Sep 2014 --> Dec 2014 Trial primary completion date: Oct 2014 --> Oct 2015
- || Tasigna (nilotinib) / Novartis, Inhibikase
Trial completion date: Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study (clinicaltrials.gov) - May 26, 2014
P4, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Oct 2014 --> Oct 2015 Trial completion date: Jul 2023 --> May 2024
- buparlisib (AN2025) / Novartis, Adlai Nortye
Trial completion date, Combination therapy, Stroma: A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients (clinicaltrials.gov) - May 26, 2014
P1, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jul 2023 --> May 2024 Trial completion date: Sep 2014 --> Dec 2014
- linsitinib (ASP7487) / VasaraGen
Enrollment change, Stroma: Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors (clinicaltrials.gov) - May 26, 2014
P2, N=20, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2014 --> Dec 2014 N=40 --> 20
- sapanisertib (CB-228) / Calithera
Enrollment open, IO biomarker, Surgery: Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - May 26, 2014
P=N/A, N=40, Recruiting, Sponsor: National Cancer Institute (NCI)
N=40 --> 20 Not yet recruiting --> Recruiting
- | lapatinib / Generic mfg.
Trial completion: Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors (clinicaltrials.gov) - May 25, 2014
P2, N=52, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | imatinib / Generic mfg.
Trial completion, Stroma: Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor (clinicaltrials.gov) - May 25, 2014
P2, N=63, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Stroma: Prospective Database of Gastrointestinal Stromal Cell Tumors (GISTs) (clinicaltrials.gov) - May 22, 2014
P=N/A, N=187, Completed, Sponsor: Washington University School of Medicine
- | Iclusig (ponatinib) / Takeda, Otsuka
Enrollment open, Stroma, Metastases: A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (clinicaltrials.gov) - May 22, 2014
P2, N=45, Recruiting, Sponsor: Ariad Pharmaceuticals
Active, not recruiting --> Completed Suspended --> Recruiting
- leucovorin calcium / Generic mfg.
Trial initiation date, Combination therapy: Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas (clinicaltrials.gov) - May 21, 2014
P1, N=39, Not yet recruiting, Sponsor: City of Hope Medical Center
Suspended --> Recruiting Initiation date: Apr 2014 --> Apr 2015
- Recentin (cediranib) / AstraZeneca
Trial completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - May 21, 2014
P2, N=47, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Apr 2014 --> Apr 2015 Trial completion date: Jun 2014 --> Apr 2016
- Erivedge (vismodegib) / Roche
Biomarker, Trial completion, Surgery: GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery (clinicaltrials.gov) - May 20, 2014
P2, N=46, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2014 --> Apr 2016 Active, not recruiting --> Completed
- Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion: Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma (clinicaltrials.gov) - May 20, 2014
P1, N=61, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion: VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide (clinicaltrials.gov) - May 20, 2014
P2, N=43, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology, Torisel (temsirolimus) / Pfizer
Trial completion, Combination therapy: Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma (clinicaltrials.gov) - May 20, 2014
P1/2, N=80, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed